News Image

NYSE:NVO is showing good growth, while it is not too expensive.

By Mill Chart

Last update: Apr 15, 2024

Here's NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for you, a growth stock our stock screener believes is undervalued. NYSE:NVO is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. Let's break it down further.

Growth Examination for NYSE:NVO

ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NYSE:NVO scores a 7 out of 10:

  • NVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.33%, which is quite impressive.
  • Looking at the last year, NVO shows a very strong growth in Revenue. The Revenue has grown by 31.26%.
  • Measured over the past years, NVO shows a quite strong growth in Revenue. The Revenue has been growing by 15.74% on average per year.
  • NVO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.23% yearly.
  • The Revenue is expected to grow by 13.61% on average over the next years. This is quite good.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

Deciphering NYSE:NVO's Valuation Rating

ChartMill employs its own Valuation Rating system for all stocks. This score, ranging from 0 to 10, is determined by evaluating different valuation factors, including price to earnings and free cash flow, both in absolute terms and relative to the market and industry. NYSE:NVO has earned a 5 for valuation:

  • NVO's Price/Earnings ratio is rather cheap when compared to the industry. NVO is cheaper than 80.61% of the companies in the same industry.
  • NVO's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NVO is cheaper than 78.57% of the companies in the same industry.
  • 78.57% of the companies in the same industry are more expensive than NVO, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, NVO is valued a bit cheaper than 79.08% of the companies in the same industry.
  • NVO has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as NVO's earnings are expected to grow with 22.90% in the coming years.

What does the Health looks like for NYSE:NVO

ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NYSE:NVO was assigned a score of 7 for health:

  • An Altman-Z score of 13.40 indicates that NVO is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 13.40, NVO belongs to the best of the industry, outperforming 90.82% of the companies in the same industry.
  • The Debt to FCF ratio of NVO is 0.39, which is an excellent value as it means it would take NVO, only 0.39 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 0.39, NVO belongs to the best of the industry, outperforming 96.43% of the companies in the same industry.
  • NVO has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
  • NVO does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.

What does the Profitability looks like for NYSE:NVO

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NYSE:NVO has achieved a 9:

  • NVO's Return On Assets of 26.61% is amongst the best of the industry. NVO outperforms 98.47% of its industry peers.
  • NVO has a Return On Equity of 78.53%. This is amongst the best in the industry. NVO outperforms 98.47% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 56.78%, NVO belongs to the top of the industry, outperforming 99.49% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for NVO is significantly above the industry average of 16.71%.
  • The last Return On Invested Capital (56.78%) for NVO is above the 3 year average (50.71%), which is a sign of increasing profitability.
  • With an excellent Profit Margin value of 36.03%, NVO belongs to the best of the industry, outperforming 95.92% of the companies in the same industry.
  • NVO has a better Operating Margin (44.16%) than 97.96% of its industry peers.
  • The Gross Margin of NVO (84.60%) is better than 87.24% of its industry peers.

Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.

Check the latest full fundamental report of NVO for a complete fundamental analysis.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

NOVO-NORDISK A/S-SPONS ADR

NYSE:NVO (4/29/2024, 1:34:06 PM)

126.76

-0.09 (-0.07%)

NVO News

News Image7 hours ago - The Motley FoolBillionaire Investor Jim Simons Just Bought These 3 "Magnificent Seven" Stocks

The "Magnificent Seven" stocks dominate the artificial intelligence (AI) arena. One notable hedge fund manager has three in his top 10 holdings.

News Imagea day ago - The Motley FoolIs Viking Therapeutics Incredibly Undervalued?

The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.

News Image2 days ago - The Motley FoolForget Nvidia, These Unstoppable Stocks Are Better Buys

These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.

News Image2 days ago - The Motley Fool1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On

Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.

News Image3 days ago - Market News VideoInteresting NVO Put And Call Options For June 7th
News Image4 days ago - ChartmillIs NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) a Strong Candidate for Quality Investing?

Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a quality stock.

News Image5 days ago - InvestorPlace3 Biotech Stocks With Skyrocketing Potential: April 2024

These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time.

News Image5 days ago - The Motley FoolMeet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market

Lilly recently announced news that could solve a big problem.

News Image5 days ago - InvestorPlace3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains

These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.

News Image5 days ago - The Motley FoolMissed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Good news could be just around the corner for two drugmakers not named Novo Nordisk.

News Image6 days ago - The Motley FoolBetter Buy: Pfizer vs. Viking Therapeutics

These two pharma stocks have followed distinct paths of late. Which is the better investment?

News Image6 days ago - InvestorPlace3 Stocks With the Potential to Surpass Analyst Expectations for 2024

These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth.

NVO Links
Follow us for more